IDEXX Laboratories (NASDAQ:IDXX) Earning Somewhat Positive Media Coverage, Analysis Shows

News coverage about IDEXX Laboratories (NASDAQ:IDXX) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. IDEXX Laboratories earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9225896735538 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of IDEXX Laboratories (IDXX) opened at $186.59 on Wednesday. The stock has a market cap of $16,290.71, a PE ratio of 62.89, a P/E/G ratio of 2.08 and a beta of 0.42. IDEXX Laboratories has a fifty-two week low of $120.23 and a fifty-two week high of $187.66. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.05. The company had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.62 EPS. equities analysts predict that IDEXX Laboratories will post 3.23 earnings per share for the current year.

A number of research firms recently issued reports on IDXX. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective on the stock in a report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Piper Jaffray Companies started coverage on IDEXX Laboratories in a report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $181.71.

In other news, CEO Jonathan W. Ayers sold 2,160 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the transaction, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at $179,910,017.36. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $153.75, for a total value of $2,767,500.00. Following the transaction, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 130,160 shares of company stock valued at $20,019,685. 2.77% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “IDEXX Laboratories (NASDAQ:IDXX) Earning Somewhat Positive Media Coverage, Analysis Shows” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/31/idexx-laboratories-idxx-earning-somewhat-positive-press-coverage-accern-reports.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply